Toray, Japan Tobacco and Torii Launches Oral Anti-itch Drug Remitch
This article was originally published in PharmAsia News
Executive Summary
Japanese companies Toray, Japan Tobacco and Torii Pharmaceuticals March 24 launched oral anti-itch drug Remitch (nalfurafine) capsule in Japan. Originated by Toray, nalfurafine is a selective kappa-opioid receptor agonist and the first oral anti-itching treatment in Japan for hemodialysis patients resistant to existing treatments. The drug obtained approval Janu. 21 and is currently marketed by Torii. The Japan Society for Dialysis Therapy estimates there are more than 275,100 dialysis patients in Japan. (Click here for more - Japanese language